SCHEDULE 13G/A: Menora Mivtachim Holdings Discloses 4.99% Stake in UroGen Pharma Ltd.
Beneficial Ownership Report
Menora Mivtachim Holdings Ltd. has filed an amendment to its Schedule 13G, disclosing a beneficial ownership of 4.99% in UroGen Pharma Ltd.'s ordinary shares as of March 11, 2025.
Summary
- Menora Mivtachim Holdings Ltd. and its subsidiaries collectively beneficially own 2,303,031 ordinary shares of UroGen Pharma Ltd.
- This ownership represents 4.99% of UroGen Pharma Ltd.'s total ordinary shares outstanding, based on 46,094,352 shares as of March 13, 2025.
- The shares are held by various subsidiaries, including Menora Mivtachim Pensions and Gemel Ltd. (1,897,925 shares or 4.12%), Menora Mivtachim Insurance Ltd. (213,865 shares or 0.46%), and Menora Mivtachim Vehistadrut Hamehandesim Nihul Kupot Gemel Ltd. (191,240 shares or 0.41%).
- The beneficial ownership is primarily held for the benefit of insurance policyholders, owners of portfolio accounts, or members of provident/pension funds.
- Menora Holdings and its subsidiaries disclaim beneficial ownership of these securities except to the extent of their pecuniary interest.
- The securities were not acquired and are not held for the purpose of changing or influencing the control of UroGen Pharma Ltd.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, providing neutral information without expressing positive or negative sentiment regarding the issuer's performance or outlook.
Future Outlook
NA
Industry Context
This filing is a standard disclosure required when an institutional investor's beneficial ownership in a public company reaches or changes significantly, providing transparency on major shareholders. It does not provide insights into UroGen Pharma Ltd.'s operational performance or industry trends, but rather reflects an investment decision by Menora Mivtachim Holdings Ltd.
Related Party Transactions
- The beneficial ownership is held by Menora Mivtachim Holdings Ltd. and its direct or indirect, wholly-owned or majority-owned subsidiaries, including Menora Mivtachim Insurance Ltd., Shomera Insurance Company Ltd., Menora Mivtachim Pensions and Gemel Ltd., Menora Mivtachim Vehistadrut Hamehandesim Nihul Kupot Gemel Ltd., and Menora Mivtachim Investment Portfolio Management Ltd.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, which can influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 03/11/2025 | Date of event which requires the filing of this statement (beneficial ownership threshold met/changed). |
| 03/13/2025 | Date as of which 46,094,352 Ordinary Shares outstanding were reported on Bloomberg LP, used for percentage calculation. |
| 03/17/2025 | Date the Schedule 13G/A filing was signed. |
Keywords
UroGen Pharma Ltd., Menora Mivtachim Holdings Ltd., Schedule 13G, Beneficial Ownership, SEC Filing, Ordinary Shares, Institutional Investor, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.